About 10–20% of GC patients treated with anti-PD-1/PD-L1 monotherapy have adverse grade ≥3 events, including fatigue, anemia, and elevated alanine and aspartate aminotransferase levels. The gene discussed is CD274; the disease is gastric cancer.